Host Rahul Banerjee, MD, speaks with Drs. Frederik Schjesvold and Frida Askeland on myeloma trial results, relevance in the IMROZ/CEPHEUS era, and advances in treating elderly, frail patients.

MD Anderson fellows discuss AML, MRD endpoints, and evolving trial strategies in a dynamic grand rounds–style presentation.

William Wierda, MD, PhD of the University of Texas MD Anderson discusses advances in chronic lymphocytic leukemia care, from targeted therapies and resistance to immune dysfunction and prevention with Blood Cancers Today Managing Editor, Nichole Tucker.

In this Editor’s Special Episode of The HemOnc Pulse, Dr. Hira Mian of McMaster University shares expert insights on the evolving treatment landscape for multiple myeloma. From optimizing selinexor use, to understanding long-term MonumenTAL-1 data with talquetamab, to the promise of emerging trispecific antibodies, Dr. Mian highlights the biggest shifts shaping care today.

A panel of hematology leaders discusses the latest in ALL and T-cell ALL therapy, including TKI+blina combinations, venetoclax strategies, and the emerging role of CD7 CAR T-cell therapies in reshaping treatment paradigms.

Review of IMerge phase 3 data on imetelstat for lower-risk MDS and how prior therapies affect treatment outcomes, and other ASCO 2025 MDS updates with Andrew Brunner, MD.

During a session at The HemOnc Pulse Live! moderated by Naval Daver, MD, Eunice Wang, MD presents new insights in acute myeloid leukemia care, joined by Aditi Shastri, MBBS, Tapan Kadiya, MD, and Kelly Chien, MD for a rich panel on mutation loss, minimal residual disease, and transplant timing.

Drs. Gurbakhash Kaur and Danai Dima discuss next-gen CAR T and bispecific therapies for myeloma, including agents for extramedullary disease and GPRC5D targets.

In this Editor’s Special of The HemOnc Pulse, Tycel Phillips, MD, joins an editor of Blood Cancers Today to break down the latest research in B-cell non-Hodgkin lymphoma presented at the 2025 ASCO Annual Meeting. The conversation spans follicular lymphoma, CLL, mantle cell lymphoma, and large B-cell lymphoma, covering key insights on BTK/BCL2 inhibitors, bispecifics, CAR T-cell therapy, and more.

Hematologist-oncologist Dr. Alexey Danilov shares expert insights on chronic lymphocytic leukemia, highlighting unmet needs in immune management, the challenges of Richter’s transformation, and promising data on BTK degraders for double-refractory patients.